Acumen updates ACU193 Phase 1 subcutaneous trial to mid-2024; secures $50M credit facility

Acumen Pharmaceuticals, Inc.

Projected mid-2024 initiation of Phase 1 subcutaneous trial for ACU193.
Reported results from recent FDA interaction regarding ACU193 development.
Additional CSF biomarker data from Phase 1 INTERCEPT-AD trial presented.
New credit facility of up to $50 million from K2 HealthVentures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.